AI-driven Drug Optimization
Design better molecules faster while reducing cost and experimental iterations.
MedMap integrates generative AI, medicinal chemistry rules, ADMET prediction, docking, reinforcement learning, PK/PD simulation and DMTA project learning into a service platform for real lead-optimization programs.
DMTA
closed-loop learning
40+
ADMET endpoints
AI
generation + ranking
ADC
optimization support
Optimization loop
Every experimental cycle updates SAR, liability patterns and the next design strategy.
Why MedMap
Traditional discovery programs lose time and budget between design cycles. MedMap helps teams focus computational and experimental resources on candidates with better potency, ADMET, docking, developability and IP profiles.
Average discovery-to-market timeline before a successful therapy reaches patients.
Clinical failure risk, often driven by efficacy, safety, DMPK and translational gaps.
Estimated average cost per approved drug when failed programs are included.
Faster virtual screening and prioritization across larger chemical spaces.
ADMET and DMPK/toxicity endpoints to identify liabilities before synthesis.
DMTA knowledge base captures SAR, experimental feedback and decision rationale cycle by cycle.
Core platform capabilities
Each module can be delivered as a focused service or combined into an end-to-end optimization program.
Generate and refine analogs using a hybrid design pipeline that combines model-driven exploration with medicinal chemistry constraints.
Design, Make, Test and Analyze are connected into a learning loop so each experimental result improves the next round of design.
Outputs include candidate ranking, liability interpretation and a next-cycle action plan.
Evaluate developability risk early with machine-learning predictions across absorption, distribution, metabolism, excretion and toxicity.
Docking is adapted to ligand class and target context, then interpreted with pose confidence and medicinal chemistry narratives.
Featured capability
A defect-driven optimization engine that turns candidate weaknesses into focused medicinal chemistry actions instead of generating random analogs.
Input
Defects
Action
Edits
Output
Re-score
Reads ADMET, toxicity, docking, selectivity and patent/FTO signals to identify the main blocker for each candidate.
Uses directed RDKit transformations such as polar rescue, F-blocking, ring swaps, bioisosteres and scaffold hops.
Re-ranks optimized analogs with QSAR, ADMET-AI, docking and patent-aware screening before the next DMTA cycle.
Uncertainty-aware multi-objective reinforcement learning balances potency, ADMET, synthesis, novelty and confidence.
Translate molecular properties into exposure, target occupancy and response scenarios before committing to expensive experiments.
For antibody-drug conjugate development, MedMap supports multi-dimensional CQA scoring, linker/payload design, clinical translation prediction and ADC-specific PK/PD simulation.
Engagement model
MedMap can support a single optimization question or a complete lead-optimization cycle. Typical inputs include reference compounds, target information, assay context, medicinal chemistry constraints and project-specific developability goals.
Ranked analogs with potency, ADMET, docking, synthesis and FTO summaries.
Targeted edits for hERG, CYP, AMES, solubility, clearance and pose weaknesses.
Actionable synthesis, assay and next-round optimization recommendations.
Talk with MedMap about your target, seed compound, lead series or ADC design challenge. We can scope a focused proof-of-concept or a complete AI-guided DMTA program.
Contact MedMap